Skip to main content
Top
Published in: Digestive Diseases and Sciences 5/2024

22-03-2024 | Primary Sclerosing Cholangitis | Original Article

Primary Sclerosing Cholangitis: Gender Effects in Valencia’s Low-Prevalence Region

Authors: Alejandro Mínguez, Isabel Conde, Cristina Montón, Lara Gonzalez, Sonia Pascual, María Dolores Antón, Antonio Palau, Ana Forés, Concha Gisbert, Asunción Ojeda, Eva Girona, Tommaso Di Maira, Marina Berenguer

Published in: Digestive Diseases and Sciences | Issue 5/2024

Login to get access

Abstract

Background and Aims

Recent studies point out to epidemiological changes in primary sclerosing cholangitis (PSC). Our aims were to determine in PSC patients followed in several centers in a Mediterranean geographic area: (i) changes in baseline features and (ii) effect of gender on clinical course.

Methods

Retrospective multicenter study of PSC patients treated in 8 hospitals in a Mediterranean area between 2000 and 2021. Charts were reviewed compiling demographic, clinical, radiological, and histological variables.

Results

Cohort of 112 PSC patients included, 42% women, 70% diagnosed after 2010. Women were increasingly diagnosed in recent cohorts. The median time from diagnosis to the combined endpoint liver transplantation (Lt) and/or death was 6.9 years. Asthenia at diagnosis (p = 0.009) was associated with lower transplant-free survival, while diagnosis before 2005 was associated with greater LT-free survival (p < 0.001). By Cox regression, LT-free survival was not influenced by age, sex, or cirrhosis at the time of diagnosis. Women were found to have less jaundice at diagnosis (2 vs 14%; p = 0.013), higher prevalence of ANA antibodies (43.9 vs 15.7%; p = 0.003), and lower GGT levels at diagnosis (GGT 123 vs 209U/L; p = 0.014) than men.

Conclusion

In an area traditionally considered to have low prevalence, the prevalence of affected women surpasses expectations based on existing literature. There appear to be gender-related variations in the presentation of the condition, highlighting the need for confirmation through larger-scale studies.
Literature
1.
go back to reference Berdal JE, Ebbesen J, Rydning A. [Incidence and prevalence of autoimmune liver diseases] Insidens og prevalens av autoimmune leverlidelser. Tidsskr Nor Laegeforen 1998;118:4517e9. Berdal JE, Ebbesen J, Rydning A. [Incidence and prevalence of autoimmune liver diseases] Insidens og prevalens av autoimmune leverlidelser. Tidsskr Nor Laegeforen 1998;118:4517e9.
28.
go back to reference Kitahora T, Utsunomiya T, Yokota A. Epidemiological study of ulcerative colitis in Japan: incidence and familial occurrence. J Gastroenterol 1995;30:5–8.PubMed Kitahora T, Utsunomiya T, Yokota A. Epidemiological study of ulcerative colitis in Japan: incidence and familial occurrence. J Gastroenterol 1995;30:5–8.PubMed
Metadata
Title
Primary Sclerosing Cholangitis: Gender Effects in Valencia’s Low-Prevalence Region
Authors
Alejandro Mínguez
Isabel Conde
Cristina Montón
Lara Gonzalez
Sonia Pascual
María Dolores Antón
Antonio Palau
Ana Forés
Concha Gisbert
Asunción Ojeda
Eva Girona
Tommaso Di Maira
Marina Berenguer
Publication date
22-03-2024

Other articles of this Issue 5/2024

Digestive Diseases and Sciences 5/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine